Barbara A. Farley
University of Rochester
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Barbara A. Farley.
Leukemia Research | 1987
James F. Leary; Betsy M. Ohlsson-Wilhelm; Rita Giuliano; Sandra Labella; Barbara A. Farley; Peter T. Rowley
K562 cells have been reported to display a variety of non-erythroid properties. Using 28 lineage-specific monoclonal antibodies, we analysed which antigens are present spontaneously and which are inducible by a variety of agents. The data suggest that (1) antigens of a given lineage are preferentially responsive to certain inducers, e.g. megakaryocytic antigens to phorbol ester, and (2) a given inducer may influence antigens of different lineages in opposite directions, e.g. phorbol dibutyrate, not only induces megakaryocytic antigens, but also decreases granulocyte and erythroid antigens. We conclude that the K562 cell, despite its malignant origin, retains some capacity for expression of alternative programs of differentiation, a characteristic of the normal multipotent hematopoietic stem cell.
Leukemia Research | 1992
Peter T. Rowley; Barbara A. Farley; Rita Giuliano; Sandra Labella; James F. Leary
Agents which induce monocytic characteristics in HL-60 human acute promyelocytic leukemia cells induce mRNA for the fms proto-oncogene, which encodes the receptor for M-CSF. Previous studies of fms expression in HL-60 cells have characterized chiefly induction by phorbol esters of fms mRNA. Our studies of fms expression in HI-60 cells have characterized induction by vitamin D3 of the fms protein. We have used flow cytometry to correlate fms antigen with a monocyte-specific differentiation antigen recognized by antibody MO2 (CD14), with DNA content, and with the nuclear antigen Ki-67, a marker of cell cycling. HL-60 cells were cultured with or without 1 microM vitamin D for 7 days. fms antigen was found on 42 +/- 5.8% of the cells cultured without vitamin D, but on 63 +/- 4.3% of the cells cultured with vitamin D. MO2 binding was detected on only 2 +/- 0.5% of the cells without vitamin D, but on 59 +/- 9% with vitamin D. Cells cultured with vitamin D that were fms-positive were also predominantly (83%) MO2-positive. Analysis of DNA content, measured by propidium iodide staining, showed that 57 +/- 1.5% of cells cultured without vitamin D, but 93 +/- 0.5% of cells cultured with vitamin D, were in the G0/G1 cell cycle phase. Analysis of nuclear antigen Ki-67 revealed that, of the vitamin D-treated cells that were fms-positive, a significant proportion (37%) were still cycling. We conclude that (1) fms is demonstrable on some uninduced HL-60 cells, (2) when HL-60 cells are induced to develop monocytic characteristics by vitamin D, fms induction is part of the program for monocytic differentiation that includes MO2 expression, yet (3) some induced cells expressing fms are still cycling.
Archives of Biochemistry and Biophysics | 1985
Betsy M. Ohlsson-Wilhelm; Barbara A. Farley; Natalie S. Rudolph; Peter T. Rowley
K562 cells are human leukemia cells inducible for hemoglobin synthesis by a variety of agents. This report demonstrates that hypoxanthine, which alone has no inductive effect, enhances induction by thymidine, resulting in a greater absolute, as well as relative, percentage of benzidine positive cells. This effect is seen over a 20-fold concentration range for both thymidine and hypoxanthine. This enhancement involves commitment, i.e., a process in which the induction of hemoglobin synthesis is coupled to a limitation in the number of subsequent cell divisions. Although thymidine alone increases the percentage of cells in S phase, hypoxanthine does not augment this. Purines other than hypoxanthine also enhance induction by thymidine. This enhancement by hypoxanthine of thymidine induction is inhibited by pyrimidine nucleosides. Mycophenolic acid, an inhibitor of IMP dehydrogenase, itself an effective K562 inducer, is not additive to thymidine and hypoxanthine, suggesting that hypoxanthine may act by reducing the supply of guanosine nucleosides.
Proceedings of the National Academy of Sciences of the United States of America | 1978
Peter T. Rowley; Betsy M. Ohlsson-Wilhelm; Barbara A. Farley
Blood | 1991
Barry M. Goldstein; James F. Leary; Barbara A. Farley; Victor E. Marquez; Paul C. Levy; Peter T. Rowley
Stem Cells | 1992
Peter T. Rowley; Barbara A. Farley; Sandra Labella; Rita Giuliano; James F. Leary
Blood | 1985
Peter T. Rowley; Bm Ohlsson-Wilhelm; Barbara A. Farley
Blood | 1982
Peter T. Rowley; Bm Ohlsson-Wilhelm; Ns Rudolph; Barbara A. Farley; B Kosciolek; S LaBella
Proceedings of the National Academy of Sciences of the United States of America | 1979
Peter T. Rowley; Betsy M. Ohlsson-Wilhelm; Barbara A. Farley; Barbara A. Kosciolek
Blood | 1981
Peter T. Rowley; Bm Ohlsson-Wilhelm; Barbara A. Farley